Logo

Amgen and Allergan Report Results of ABP 798 (biosimilar- rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma

Share this

Amgen and Allergan Report Results of ABP 798 (biosimilar- rituximab) in JASMINE Study for Non-Hodgkin's Lymphoma

Shots:

  • The JASMINE study involves assessing of ABP 798 vs its reference product- Rituximab at a dose of 375 mg/m2 (IV- qw) for 4wks. followed by dosing at weeks 12 and 20 in 256 patients with non-Hodgkin's lymphoma
  • The JASMINE study results demonstrated bio-similarity data in its 1EPs i.e- ORR @28wks. and clinical equivalence to Rituxan. Additionally- the companies conducted a clinical study of ABP 798 in mod. to sev. RA patients resulting in clinical equivalence & pharmacokinetic similarity
  • ABP 798 is an anti-CD20 mAb having the same amino acid sequence as the reference product- Rituxan. In Dec 2011- Amgen and Allergan entered into a WW collaboration to develop & commercialize four oncology antibody biosimilar therapies

Click here to­ read full press release/ article | Ref: Amgen | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions